On the role of HLA antibodies in hematopoietic stem cell transplantation

Tissue Antigens

Volumn 81, Issue 1, 2013, Pages 1-11

  Brand, A ^a,b   Doxiadis, I N ^b   Roelen, D L ^b  

^a Europdonor Foundation   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cord blood; Donor specific antibodies; Graft failure; Hematopoietic stem cell transplantation; HLA antibodies

Indexed keywords

CD34 ANTIGEN; CHEMOKINE; CYTOKINE; FC RECEPTOR; HLA ANTIBODY; IMMUNOGLOBULIN G ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ANTIGEN EXPRESSION; BLOOD DONOR; BLOOD GROUP TYPING; BONE MARROW TRANSPLANTATION; COMPLEMENT DEPENDENT LYMPHOCYTOTOXICITY TEST; COMPLEMENT MEDIATED CELL LYSIS; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXICITY TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE TRANSFUSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTE TRANSFUSION; TRANSFUSION RELATED ACUTE LUNG INJURY;

GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ISOANTIBODIES;

EID: 84870715919     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/tan.12040     Document Type: Review

References (60)

1. Pollack MS. Histocompatibility testing for bone marrow/stem cell transplantation of matched and partially mismatched donors. In: Guidelines for Clinical Histocompatibility Practice. Lenexa, Kansas, ASHI, 1999, 49-53.
2. Gutman JA, McKinney SK, Pereira S et al. Prospective monitoring for alloimmunization in cord blood transplantation: "virtual crossmatch" can be used to demonstrate donor-directed antibodies. Transplantation 2009: 87: 415-8.
3. Yoshihara S, Taniguchi K, Ogawa H, Saji H. The role of HLA antibodies in allogeneic SCT: is the "type and screen" strategy necessary not only for blood type but also for HLA? Bone Marrow Transplant 2012: 1-8. DOI: 10.1038/bmt2011.249.
4. Tait BD, Hudson F, Brewin G, Cantwell L, Holdsworth R. Solid phase HLA antibody detection technology-challenges in interpretation. Tissue Antigens 2010: 76: 87-95.
5. Liu C, Wetter L, Pang S, Phelan DL, Mohanakumar T, Morris GP. Cutoff values and data handling for solid-phase testing for antibodies to HLA: effects of listing unacceptable antigens for thoracic organ transplantation. Hum Immunol 2012: 73: 597-604.
6. Duquesnoy RJ, Witvliet MJ, Doxiadis INN, de Fijter H, Claas FHJ. HLA matchmaker based strategy to identify acceptable HLA-class I mismatches for highly sensitized kidney transplant candidates. Transpl Int 2004: 17: 22-30.
7. Ellis TM, Schiller JJ, Roza AM, Cronin DC, Shames BD, Johnson CP. Diagnostic accuracy of solid phase HLA antibody assays for prediction for prediction of crossmatch strength. Hum Immunol 2012: 73: 706-10.
8. Roelen DL, Doxiadis II, Claas FHJ. Detection and clinical relevance of donor specific HLA antibodies: a matter of debate. Transpl Int 2012: 25: 604-10.
9. Vassallo RR, Hsu S, Einarson M, Barone J, Brodsky J, Moroff G. A comparison of two robotic platforms to screen plateletpheresis donors for HLA antibodies as part of a transfusion-related acute lung injury mitigation strategy. Transfusion 2010: 50: 1766-77.
10. Lopes LB, Fabron A, Chiba AK, Ruiz MO, Bordin JO. Impact of using different laboratory assays to detect human leukocyte antigen antibodies in female blood donors. Transfusion 2010: 50: 902-8.
11. Morales-Buenrostro LE, Terasaki PI, Marino-Vasquez LA, Lee JH, El-Awar N, Alberu J. "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008: 86: 1111-5.
12. Zoet YM, Brand-Schaaf SH, Roelen DL, Mulder A, Claas FH, Doxiadis II. Challenging the golden standard in defining donor-specific antibodies: does the solid phase assay meet expectations? Tissue Antigens 2011: 77: 225-8.
13. Densmore TL, Goodnough LT, Ali S, Dynis M, Chaplin H. Prevalence of HLA sensitisation in female apheresis donors. Transfusion 1999: 39: 103-6.
14. Powers A, Stowell CP, Dzik WH, Saidman S, Lee H, Makar RS. Testing only donors with a prior history of pregnancy or transfusion is a logical and cost-effective transfusion-related acute lung injury prevention strategy. Transfusion 2008: 48: 2549-58.
15. Sachs UJH, Link E, Hofmann C, Wasel W, Bein G. Screening of multiparous women to avoid transfusion-related acute lung injury: a single centre experience. Transfusion Medicine 2008: 18: 348-54.
16. Reil A, Keller-Stanislawski S, Bux J. Specificities of leukocyte alloantibodies in transfusion-related acute lung injury and results of leukocyte antibody screening of blood donors. Vox Sang 2008: 95: 313-7.
17. Kakaiya RM, Triulzi DJ, Wright DJ et al. Prevalence of HLA antibodies in remotely transfused or alloexposed blood donors. Transfusion 2010: 50: 1328-34.
18. Middelburg RA, Porcelijn L, Lardy N, Briet E, Vrielink H. Prevalence of leukocyte antibodies in the Dutch donor population. Vox Sang 2010: 100: 327-35.
19. Payne R. The development and persistence of leukoagglutinins in parous women. Blood 1962: 19: 411-24.
20. Trial to Reduce Alloimmunization to Platelets (TRAP) Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. New Engl J Med 1997: 337: 1861-9.
21. Van de Watering L, Hermans J, Witvliet M, Versteegh M, Brand A. HLA and RBC immunization after filtered and buffy-coat depleted blood transfusion in cardiac surgery: a randomized trial. Transfusion 2003: 43: 765-71.
22. Ohto H, Nomizu T, Kuroda F, Hoshi T, Rokkaku Y. HLA alloimmunization of surgical patients by transfusion with bedside leuko reduced blood components. Fukushima J Med Sci 2003: 49: 45-54.
23. Karpinski M, Pochinco D, Dembinski I, Laidlaw W, Zacharias J, Nickelson P. Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in prospective kidney transplant candidates. J Am Soc Nephrol 2004: 15: 818-24.
24. Storb R, Prentice RL, Thomas ED et al. Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection. N Engl J Med 1977: 296: 61-6.
25. Takanashi M, Fujiwara K, Tanaka H, Satake M, Nakajima K. The impact of HLA antibodies on engraftment of unrelated cord blood transplants. Transfusion 2008: 48: 791-2.
26. Spellman S, Bray R, Rosen-Bronson S et al. The detection of donor-directed, HLA-specific antibodies in recipients of unrelated hematopoietic cell transplantation is predictive for graft failure. Blood 2010: 115: 2704-8.
27. Ciurea SO, de Lima M, Cano P et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem cell-transplantation. Transplantation 2009: 88: 1019-24.
28. Takanashi M, Atsura Y, Fujiwara K et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood 2010: 116: 2839-46.
29. Yoshihara S, Maruya E, Taniguchi K et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant 2012: 47: 508-15.
30. Brunstein CG, Noreen H, Defor TE, Maurer DMiller JS, Wagner JE. Anti-HLA antibodies in double umbilical cord blood transplantation. Biol Blood Marrow Transplant 2011: 17: 1704-8.
31. Ciurea SO, Thall PF, Wang A et al. Donor-specific anti-HLA antibodies and graft failure in matched unrelated donor transplantation. Blood 2011: 118: 5957-64.
32. Ansari M, Uppugunduri C, Bittencourt H et al. Anti-HLA antibodies and outcome in paediatric cord blood transplantation. Abstract 0248 EBMT 2012; S42.
33. Ruggeri A, Rocha V, Masson E, et al. Impact of donor specific anti-HLA antibodies on graft failure and survival after cord blood transplantation with reduced -intensity conditioning regimen. An Eurocord, SFGM-TC and SFHI analysis. Abstract 0326 EBMT 2012: S66.
34. Mickelson EM, Petersdorf E, Anasetti C, Martin P, Woolfrey A, Hansen JA. HLA matching in hematopoietic cell transplantation. Hum Immunol 2000: 61: 92-100.
35. Uchiyama M, Ikeda T. Successful engraftment following umbilical cord transplantation for patients with HLA antibody with or without corresponding HLA in the transplanted cord. Bone Marrow Transpl 2010: 45: 199-200.
36. Cutler C, Kim HT, Sun L et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood 2011: 118: 6691-7.
37. Detrait M, Dubois V, Sohb M, et al. Impact of anti-HLA antibodies on allogeneic hematopoietic stem cell transplantation outcomes after reduced-intensity conditioning regimens. Exp Hematol 2012: 40: 792-9.
38. Falkenburg FH, Jansen J, van der Vaart-Duinkerken N et al. Polymorphic and monomorphic HLA-DR determinants on human hematopoietic progenitor cells. Blood 1984: 63: 1125-32.
39. Piacibello W, Aglietta M, Stacchini A et al. Expression of HLA class II determinants by normal and chronic myeloid leukemia progenitors. Leuk Res 1987: 11: 285-90.
40. Busch FW, Langer M, Pawelec G et al. HLA class II antigens on hematopoietic progenitors. Blut 1987: 54: 179-88.
41. Callender CJ, Fernandez-Vina M, Leffell M, Zachary A. Frequency of HLA-DP-specific antibodies and a possible new cross-reactive group. Human Immunology 2012: 73: 175-9.
42. Xu H, Chilton PM, Tanner MK et al. Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitised recipients. Blood 2006: 108: 3611-9.
43. Taylor PA, Ehrhardt MJ, Roforth MM et al. Preformed antibodies, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood 2007: 109: 307-15.
44. Anasetti C, Amos D, Beatty PG et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukaemia or lymphoma. New Engl J Med 1989: 320: 197-204.
45. Ottinger HD, Rebmann V, Pfeiffer KA et al. Positive serum crossmatch as predictor for graft failure in HLA-mismatched allogeneic blood stem cell transplantation. Transplantation 2002: 73: 1280-5.
46. Barge AJ, Johnson G, Witherspoon R, Torok-Storb B. Antibody-mediated marrow failure after allogeneic bone marrow transplantation. Blood 1989: 74: 1477-80.
47. Maruta A, Fukawa H, Kanamori H et al. Donor-HLA-incompatible marrow transplantation with an anti-donor cytotoxic antibody in the serum of the patient. Bone Marrow Transplant 1991: 7: 397-400.
48. Braun N, Faul C, Wernet D, Schnaidt M et al. Successful transplantation of highly selected CD34+ peripheral blood stem cells in a HLA-sensitized patient treated with immunoadsorption onto protein A. Transplantation 2000: 69: 1742-4.
49. Pollack MS, Ririe D. Clinical significance of recipient antibodies to stem cell donor mismatched class I HLA antibodies. Human Immunol 2004: 65: 245-7.
50. Narimatsu H, Wake A, Miura Y et al. Successful enraftment in crossmatch-positive HLA-mismatched peripheral blood stem cell transplantation after depletion of antidonor cytotoxic HLA antibodies with rituximab and donor platelet infusion. Bone Marrow Transplant 2005: 36: 555-6.
51. Nordlander A, Uhlin M, Ringden O, Kumlien G, Hauzenberger D, Mattson J. Immune modulation to prevent antibody-mediated rejection after allogeneic hematopoietic stem cell transplantation. Transpl Immunol 2011: 25: 153-8.
52. Abou-Elella AA, Camarillo TA, Allen MB. Low incidence of red cell and HLA antibody formation by bone marrow transplant patients. Transfusion 1995: 35: 931-5.
53. Lapierre V, Auperin A, Tayebi H. Increased presence of anti HLA antibodies early after allogeneic granulocyte colony-stimulating factor mobilized peripheral blood hematopoietic stem cell transplantation compared with bone marrow transplantation. Blood 2002: 100: 1484-9.
54. Leffell MS, Cao K, Coppage M et al. Incidence of humoral sensitisation in HLA partially mismatched hematopoietic stem cell transplantation. Tissue Antigens 2009: 74: 494-8.
55. th International HLA and immunogenetics workshop: report on understanding antibodies in transplantation. Tissue Antigens 2007: 69: 160-73.
56. Morrow WR, Fraier EA, Mahle WT et al. Rapid reduction in donor-specific anti human leukocyte antigen antibodies and reversal of antibody mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation 2012: 93: 319-24.
57. Guthoff M, Schmidt-Horch B, Weisel KC, Haring HU, Konigsrainer A, Heyne N. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitised patients awaiting renal allograft transplantation. Transpl Immunol 2012: 26: 171-5.
58. Tambur AR, Leventhal JR, Friedewald JJ, Ramon DS. The complexity of human leukocyte antigen (HLA)-DQ antibodies and its effect on virtual crossmatching. Transplantation 2010: 90: 1117-24.
59. Delaney M, Cutler CS, Haspel RL et al. High-resolution HLA matching in double-umbilical cord reduced intensity transplantation in adults. Transfusion 2009: 49: 995-1002.
60. Nordlander A, Mattsson J, Sundberg B, Sumitran-Holgersson S. Novel antibodies to the donor stem cell population CD34+/VEGF-2+ are associated with rejection after hematopoietic stem cell transplantation. Transplantation 2008: 86: 686-96.